Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Background Stalled progress in controlling Plasmodium falciparum malaria highlights the
need for an effective and deployable vaccine. RTS, S/AS01, the most effective malaria …

Malaria—a parasite vector-borne disease—is a global health problem, and Plasmodium
falciparum has proven to be the deadliest among Plasmodium spp., which causes malaria in …

Abstract The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
was formed to evaluate the safety and characteristics of live, recombinant viral vector …

A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …

Malaria remains one of the biggest health problems in the world. While significant reductions
in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend …

Monoclonal antibodies are highly specific proteins that are cloned from a single B cell and
bind to a single epitope on a pathogen. These laboratory-made molecules can serve as …

Background Malaria remains a key cause of mortality in low-income countries. RTS, S/AS01
is currently the most advanced malaria vaccine, demonstrating∼ 50% efficacy in controlled …

Vaccines against parasites have lagged centuries behind those against viral and bacterial
infections, despite the devastating morbidity and widespread effects of parasitic diseases …